CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,011,725 | +100.2% | 34,019 | +21.3% | 0.01% | +100.0% |
| Q2 2023 | $505,407 | +12.2% | 28,047 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $450,435 | -12.2% | 28,047 | 0.0% | 0.00% | -25.0% |
| Q4 2022 | $513,260 | -4.1% | 28,047 | +2.9% | 0.00% | -20.0% |
| Q3 2022 | $535,288 | +12.9% | 27,255 | +7.2% | 0.01% | +25.0% |
| Q2 2022 | $474,027 | -15.0% | 25,417 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $557,903 | +20.1% | 25,417 | +55.4% | 0.00% | 0.0% |
| Q4 2021 | $464,617 | +89.5% | 16,354 | +40.4% | 0.00% | +100.0% |
| Q3 2021 | $245,190 | +11.7% | 11,648 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $219,565 | +23.4% | 11,648 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $177,981 | -0.9% | 11,648 | -8.5% | 0.00% | 0.0% |
| Q4 2020 | $179,649 | -10.0% | 12,732 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $199,510 | -10.6% | 12,732 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $223,065 | +160.1% | 12,732 | +118.2% | 0.00% | +200.0% |
| Q1 2020 | $85,775 | -41.4% | 5,835 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $146,400 | – | 5,835 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| 5AM Venture Management, LLC | 1,862,286 | $27,376,000 | 8.48% |
| Vivo Capital, LLC | 3,320,801 | $48,816,000 | 4.42% |
| Burrage Capital Management LLC | 282,272 | $4,022,000 | 3.96% |
| Opaleye Management Inc. | 368,750 | $5,421,000 | 1.44% |
| Perceptive Advisors | 2,587,953 | $38,042,000 | 0.99% |
| RA Capital Management | 1,961,209 | $28,830,000 | 0.91% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,073,000 | 0.62% |
| EcoR1 Capital, LLC | 350,000 | $5,145,000 | 0.54% |
| Orbimed Advisors | 2,039,282 | $29,977,000 | 0.50% |
| Eventide Asset Management | 947,000 | $13,921,000 | 0.45% |